Manufacturing Failures Place GMP Compliance in Spotlight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturing Failures Place GMP Compliance in Spotlight
Fallout escalates from McNeil recall and Genzyme shortages as regulators review oversight.


Pharmaceutical Technology
Volume 34, Issue 8, pp. 26-30


Jill Wechsler
For the past 10 years, the US Food and Drug Administration has campaigned for a more efficient, risk-based approach to monitoring drug-manufacturing activities. The agency's goal has been to encourage consistent production of high-quality products while providing less routine oversight. Yet, a series of serious manufacturing breakdowns in recent months has led to plant closures and massive product recalls, raising questions about industry investment in and commitment to modern production systems able to meet established regulatory standards.

In April, the McNeil unit of Johnson & Johnson (J&J, New Brunswick, NJ) shut its flagship facility in Fort Washington, Pennsylvania, and recalled millions of bottles of children's cold medicines due to repeated failures to meet manufacturing standards and comply with regulations. The problems, observed FDA Principal Deputy Commissioner Joshua Sharfstein at a Congressional hearing in May, appear related to the company's "pattern of noncompliance" with quality control requirements. J&J now faces potentially serious legal issues, as Congressional leaders have raised charges of stonewalling, and FDA is examining whether the firm knowingly misled the regulators.

Meanwhile, Genzyme (Cambridge, MA) continued its struggle to restore production capacity after contamination problems prompted the closure of its Allston Landing, Massachusetts, facility in June 2009. The company paid a hefty fine and invested millions in plant cleaning and renovation. Manufacturing issues also compelled KV Pharmaceutical (St. Louis, MO) to shut down operations and recall multiple generic products and vitamin therapies. And several vaccine manufacturers are working hard to eliminate extraneous viruses from cell banks and to correct manufacturing issues identified by FDA inspectors.

These situations raise questions about whether drug and biological manufacturers are cutting corners in their quality systems needed to comply with current good manufacturing practices (CGMPs). In 2002, FDA launched the Pharmaceutical CGMPs for the 21st Century initiative to modernize the regulation of drug manufacturing and to spur industry efforts to ensure product quality. After issuing several new policies and guidances to encourage a risk-based approach to quality control, FDA had to move the effort to the back burner as other issues, including these compliance crises, began to dominate the agency's agenda.

The current surge in manufacturing problems has placed drug quality and GMP compliance back in the spotlight at FDA. In a major speech last August (2009), FDA Commissioner Margaret Hamburg emphasized the importance of industry adherence to regulatory standards (see the October 2009 edition of Washington Report in Pharmaceutical Technology). Hamburg outlined initiatives to accelerate the correction of manufacturing violations identified during plant inspections and to streamline the process for issuing Warning Letters to companies that fail to address violations expeditiously.


In Washington this month
Those policies appear to be taking hold. FDA has increased the frequency and timeliness of its "untitled" and Warning Letters that cite ongoing manufacturing problems. This approach is a reversal of the Bush administration's targeted enforcement strategy, which was based on the idea that manufacturers would take a limited number of Warning Letters more seriously. FDA enforcement efforts may gain more clout if Congress enacts long-sought legislation to strengthen the agency's legal powers, namely by providing FDA with the ability to mandate recalls, expand civil monetary penalties, and gain easier access to company records. There's more talk of FDA injunctions and consent orders, and the pharmaceutical legal community is watching closely to see whether the government brings charges against J&J and McNeil executives for not doing more to prevent company violations of food and drug laws.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here